Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKSNASDAQ:FOLDNASDAQ:IRWDNASDAQ:MDGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$31.27+3.8%$30.93$22.90▼$36.45$5.16B0.511.77 million shs1.27 million shsFOLDAmicus Therapeutics$6.21+3.8%$7.59$5.82▼$12.65$1.91B0.642.78 million shs6.70 million shsIRWDIronwood Pharmaceuticals$0.73+3.5%$1.15$0.59▼$7.11$118.74M0.372.53 million shs2.37 million shsMDGLMadrigal Pharmaceuticals$300.76+2.1%$322.18$200.63▼$377.46$6.54B-0.91385,573 shs263,710 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes0.00%-5.13%+11.67%-3.46%+25.36%FOLDAmicus Therapeutics0.00%-10.34%-7.72%-37.97%-35.21%IRWDIronwood Pharmaceuticals0.00%-23.93%-24.99%-59.93%-89.87%MDGLMadrigal Pharmaceuticals0.00%-6.61%-7.10%-12.71%+43.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALKSAlkermes4.3449 of 5 stars3.31.00.04.23.02.51.9FOLDAmicus Therapeutics4.28 of 5 stars3.42.00.04.33.10.81.9IRWDIronwood Pharmaceuticals4.2765 of 5 stars4.12.00.03.41.70.81.9MDGLMadrigal Pharmaceuticals4.6519 of 5 stars4.50.00.04.63.54.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.67Moderate Buy$38.3322.59% UpsideFOLDAmicus Therapeutics 2.70Moderate Buy$16.22161.23% UpsideIRWDIronwood Pharmaceuticals 2.13Hold$4.78551.86% UpsideMDGLMadrigal Pharmaceuticals 2.90Moderate Buy$416.3338.43% UpsideCurrent Analyst Ratings BreakdownLatest FOLD, MDGL, ALKS, and IRWD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025ALKSAlkermesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/2/2025ALKSAlkermesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$39.00 ➝ $40.005/2/2025ALKSAlkermesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$38.00 ➝ $41.005/2/2025FOLDAmicus TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $22.005/2/2025FOLDAmicus TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$12.00 ➝ $9.005/2/2025MDGLMadrigal PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$441.00 ➝ $458.005/2/2025MDGLMadrigal PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$422.00 ➝ $460.005/2/2025MDGLMadrigal PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$394.00 ➝ $420.004/28/2025ALKSAlkermesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderperform ➝ Underperform4/28/2025ALKSAlkermesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform4/28/2025ALKSAlkermesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$38.00 ➝ $33.00(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.51B3.41$2.35 per share13.32$9.05 per share3.46FOLDAmicus Therapeutics$543.14M3.52N/AN/A$0.63 per share9.86IRWDIronwood Pharmaceuticals$351.41M0.34N/AN/A($2.21) per share-0.33MDGLMadrigal Pharmaceuticals$317.38M21.04N/AN/A$20.53 per share14.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$367.07M$2.0914.4122.822.2023.57%30.80%19.09%7/23/2025 (Estimated)FOLDAmicus Therapeutics-$151.58M-$0.09N/A14.441.51-10.62%12.44%2.60%N/AIRWDIronwood Pharmaceuticals-$1.00B-$0.03N/A2.94N/A-0.65%-0.96%0.74%N/AMDGLMadrigal Pharmaceuticals-$373.63M-$18.05N/AN/AN/AN/A-71.78%-53.25%N/ALatest FOLD, MDGL, ALKS, and IRWD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025IRWDIronwood Pharmaceuticals-$0.05-$0.14-$0.09-$0.23$67.02 million$41.14 million5/1/2025Q1 2025ALKSAlkermes$0.32$0.13-$0.19$0.13$307.53 million$306.51 million5/1/2025Q1 2025MDGLMadrigal Pharmaceuticals-$3.62-$3.32+$0.30-$3.32$112.79 million$137.25 million2/27/2025Q4 2024IRWDIronwood Pharmaceuticals$0.10$0.02-$0.08$0.02$93.85 million$90.55 million2/26/2025Q4 2024MDGLMadrigal Pharmaceuticals-$4.32-$2.71+$1.61-$2.71$97.81 million$103.32 million2/12/2025Q4 2024ALKSAlkermes$0.81$0.92+$0.11$0.88$379.74 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/AFOLDAmicus TherapeuticsN/AN/AN/AN/AN/AIRWDIronwood PharmaceuticalsN/AN/AN/AN/AN/AMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermesN/A3.042.65FOLDAmicus Therapeutics2.013.392.42IRWDIronwood PharmaceuticalsN/A3.623.62MDGLMadrigal Pharmaceuticals0.155.985.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%FOLDAmicus TherapeuticsN/AIRWDIronwood PharmaceuticalsN/AMDGLMadrigal Pharmaceuticals98.50%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.40%FOLDAmicus Therapeutics2.20%IRWDIronwood Pharmaceuticals12.90%MDGLMadrigal Pharmaceuticals22.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes2,280164.90 million154.66 millionOptionableFOLDAmicus Therapeutics480307.93 million292.23 millionOptionableIRWDIronwood Pharmaceuticals220161.81 million139.38 millionOptionableMDGLMadrigal Pharmaceuticals9022.20 million16.84 millionOptionableFOLD, MDGL, ALKS, and IRWD HeadlinesRecent News About These CompaniesMadrigal Pharmaceuticals Reports Promising Two-Year Data for Rezdiffra in MASH CirrhosisMay 12 at 9:23 AM | msn.comMadrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH CirrhosisMay 10 at 7:15 AM | globenewswire.comBridgefront Capital LLC Purchases New Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)May 10 at 5:30 AM | marketbeat.comAlgert Global LLC Buys New Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)May 10 at 4:56 AM | marketbeat.comNorthern Trust Corp Raises Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)May 10 at 4:21 AM | marketbeat.comMadrigal Pharmaceuticals, Inc. (MDGL): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside PotentialMay 10 at 4:17 AM | finance.yahoo.comFirst Trust Advisors LP Acquires 1,352 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)May 10 at 3:36 AM | marketbeat.comThe Manufacturers Life Insurance Company Sells 5,877 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)May 9 at 4:23 AM | marketbeat.comMadrigal Pharmaceuticals, Inc. (MDGL): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside PotentialMay 9 at 1:16 AM | insidermonkey.comBayesian Capital Management LP Boosts Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)May 8, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Has $1.71 Million Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)May 8, 2025 | marketbeat.comMadrigal Pharmaceuticals (MDGL): Among Billionaire John Paulson’s Stocks with Huge Upside PotentialMay 7, 2025 | insidermonkey.comWhat is B. Riley's Estimate for MDGL FY2028 Earnings?May 7, 2025 | marketbeat.comMadrigal Pharmaceuticals: An Encouraging Start For RezdiffraMay 6, 2025 | seekingalpha.comStockNews.com Upgrades Madrigal Pharmaceuticals (NASDAQ:MDGL) to HoldMay 6, 2025 | americanbankingnews.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Posts Quarterly Earnings Results, Beats Expectations By $0.30 EPSMay 5, 2025 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Bought by ArrowMark Colorado Holdings LLCMay 5, 2025 | marketbeat.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Shares Down 4.4% - What's Next?May 5, 2025 | marketbeat.comVoya Investment Management LLC Sells 33,672 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)May 5, 2025 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Sold by Mariner LLCMay 4, 2025 | marketbeat.comMadrigal's Rezdiffra, the first-ever MASH drug, beats sales projections for 4 quarters in a rowMay 3, 2025 | fiercepharma.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFOLD, MDGL, ALKS, and IRWD Company DescriptionsAlkermes NASDAQ:ALKS$31.27 +1.14 (+3.78%) Closing price 04:00 PM EasternExtended Trading$31.98 +0.71 (+2.25%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Amicus Therapeutics NASDAQ:FOLD$6.21 +0.23 (+3.85%) Closing price 04:00 PM EasternExtended Trading$6.40 +0.19 (+3.06%) As of 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Ironwood Pharmaceuticals NASDAQ:IRWD$0.73 +0.02 (+3.47%) Closing price 04:00 PM EasternExtended Trading$0.76 +0.03 (+4.12%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Madrigal Pharmaceuticals NASDAQ:MDGL$300.76 +6.12 (+2.08%) Closing price 04:00 PM EasternExtended Trading$305.67 +4.91 (+1.63%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
